Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Exclusion Criteria

• •1. Histologically confirmed keratinizing squamous cell carcinoma (WHO I)；
• •2. Distant metastasis detected by pre-treatment clinical or imaging examinations;
• •3. History of allergy to any component of monoclonal antibodies, tislelizumab, or capecitabine;
• •4. History of autoimmune diseases, except for the following conditions (eligible after evaluation):
• •1. Autoimmune-related hypothyroidism on stable thyroid hormone replacement therapy;
• •2. Type I diabetes mellitus under stable insulin therapy with controlled blood glucose;
• •5. Previous or concurrent malignancies (except those cured and disease-free for \>5 years, e.g., basal cell carcinoma, cervical carcinoma in situ);
• •6. Positive pregnancy test in women of childbearing potential;
• •7. Concurrent medical conditions that may compromise patient enrollment or safety during the study;
• •8. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia, idiopathic pneumonia, or other active pulmonary diseases;
• •9. Active psychiatric disorders or other mental conditions affecting informed consent comprehension;
• •10. Uncontrolled active infections, including tuberculosis, hepatitis B (HBsAg+), hepatitis C, or HIV (HIV antibody+);
• •11. Significant cardiovascular diseases: NYHA Class II or higher, myocardial infarction within 1 year, unstable angina, or supraventricular/ventricular arrhythmias requiring clinical intervention;
• •12. Factors affecting drug administration, distribution, metabolism, or excretion (e.g., psychiatric/neurological disorders, chronic diarrhea, ascites, pleural effusion);
• •13. Unwillingness to sign informed consent.